Eir Partners has acquired a controlling interest in QuartzBio, a life science technology firm specializing in connected sample and biomarker intelligence for clinical-stage biopharma. The Frederick, Maryland-based company, founded in 2012, provides critical data solutions that accelerate drug development. This transaction aligns with Eir Partners' strategy to invest in high-growth healthcare technology platforms.

Eir Partners, established in 2015 and headquartered in Miami, focuses on middle-market private equity investments in healthcare technology and tech-enabled services. The firm targets growth equity through control buyouts, with investment sizes typically ranging from $25 million to $125 million. QuartzBio's innovative platform addresses a key need in pharmaceutical R&D, making it an attractive platform investment.

The deal provides QuartzBio with significant capital to expand its biomarker intelligence offerings and scale operations. For Eir Partners, the acquisition adds a strategic asset in the burgeoning digital health space. The undisclosed terms reflect a standard private transaction, but the controlling stake signals Eir's confidence in QuartzBio's market position and growth trajectory.

This acquisition underscores the ongoing momentum in healthcare private equity, particularly for technology companies that enhance clinical trial efficiency. With control now secured, Eir Partners can drive operational improvements and strategic partnerships to maximize QuartzBio's value in the competitive biopharma services sector.